RE:RE:RE:RE:RE:my take away's from the conference call.There is not much to talk about until we hear (1) about the European or Australian approvals (new markets) (2) the first meeting with the FDA post the rejection ((3) new canadian clinics opening (ramp of existing market)
All the information from the rejection has been digested, and it now all hangs on the three items listed above.
FDA
If they only have to redo a physical therapy only trial, the stock will likely rally. If they have to redo the whole trial, this is not a positive.
Europe & Australia
Approval from one of these two should be a catalyst, but a rejection does not bode too well. More info ont the commercialization startegy will also be well received as they have been somewhat guarded.
Canada
They need to ramp revenues and new clinics fast, to show the business can be sustained on Canada alone in a few years. Otherwise, they are relying on (1) or (2) to make the business work.
Let's hope we get good news. I hear that the Australian approvals do not usually take too long, perhaps we'll hear something in the next few weeks.
Prokofiev
Frznrth wrote:
Do you think the lack of recent posting is anything more than disinterest and people having walked away from this stock? Its at the very least not encouraging.